var title_f24_41_25232="Slow action potential";
var content_f24_41_25232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spontaneous action potential from the sinoatrial node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal sinoatrial node generates a spontaneous slow action potential (panel A), mediated primarily by calcium currents (panel B). The resting membrane potential is -65 mV and manifests spontaneous diastolic depolarization (phase 4), due to an inward leak of sodium ions via a hyperpolarization- dependent pacemaker current (If) and a gradual decline in the delayed rectifier current (Ik), resulting in a decline in the outward flow of potassium ions; these changes are superimposed upon a background current (Ib). The net result is an increase in intracellular positivity with the potential gradually reaching -40 mV, at which point a spontaneous action potential is generated, resulting from a marked increase in the influx of calcium (ICa), followed by a slow inward calcium current (Isi), and activation of Ik and the outward movement of potassium ions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25232=[""].join("\n");
var outline_f24_41_25232=null;
var title_f24_41_25233="Treatment protocols for bladder cancer";
var content_f24_41_25233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25233/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/41/25233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14907009\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with bladder cancer in the neoadjuvant, adjuvant, or metastatic setting.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bladder cancer. Additional regimens may be added over time, particularly as treatment for bladder cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with bladder cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link&amp;anchor=H210939438#H210939438\">",
"       \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=see_link\">",
"       \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"       \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14907233\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931770276\">",
"    <span class=\"h2\">",
"     GC (gemcitabine plus cisplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53016 \" href=\"UTD.htm?13/5/13406\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H931770284\">",
"    <span class=\"h2\">",
"     MVAC (methotrexate plus vinblastine, doxorubicin, and cisplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef64950 \" href=\"UTD.htm?28/7/28798\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85676 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25233=[""].join("\n");
var outline_f24_41_25233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14907009\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14907233\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931770276\">",
"      GC (gemcitabine plus cisplatin)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H931770284\">",
"      MVAC (methotrexate plus vinblastine, doxorubicin, and cisplatin)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85676|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13406\" title=\"table 1\">",
"      Gemcitabine and cisplatin for metastatic urothelial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/7/28798\" title=\"table 2\">",
"      MVAC regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_41_25234="Periosteal chondroma";
var content_f24_41_25234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Periosteal chondroma of the hand and humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Hand. Observe the juxtacortical radiolucency present within the metaphysis of the proximal phalanx (arrow). There is a cortical indentation, with scalloping or a saucerized depression of the outer cortex and a well-defined inner margin.",
"    <br>",
"     B) Humerus. Note the rather large cortical indentation with scalloped inner margins present on the medial aspect of the metaphysis of the proximal humerus. The classic cortical saucerized depression at the outer cortex, with a well-defined inner margin, is visualized at the caudal aspect of this lesion. This is a characteristic appearance for a periosteal chondroma (juxtacortical chondroma).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25234=[""].join("\n");
var outline_f24_41_25234=null;
var title_f24_41_25235="Femoral nerve block ultrasound";
var content_f24_41_25235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Femoral nerve block ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With ultrasound guidance, the transducer is placed in the inguinal crease and the hyperechoic femoral nerve lateral to the hypoechoic pulsatile common femoral artery identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25235=[""].join("\n");
var outline_f24_41_25235=null;
var title_f24_41_25236="Ultrasound ulnar nerve after elbow fracture";
var content_f24_41_25236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the ulnar nerve after elbow fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial ultrasound images of the ulnar nerve adjacent to the medial epicondyle. The ultrasound on the top (A) is from a patient with long standing symptoms of ulnar neuropathy after an elbow fracture. The diagnosis was confirmed with electrodiagnostic studies showing ulnar motor conduction block, loss of sensory nerve action potentials, and significant motor nerve conduction velocity slowing across this site. The cross sectional area of this nerve is 31 mm",
"    <sup>",
"     2",
"    </sup>",
"    , three times the normal size of the nerve as shown in the ultrasound on the bottom (B) from an asymptomatic, age-matched control.",
"    <div class=\"footnotes\">",
"     1: region of interest (green circle) used to calculate cross-sectional area of ulnar nerve; ME: medial epicondyle; U: ulnar nerve.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25236=[""].join("\n");
var outline_f24_41_25236=null;
var title_f24_41_25237="Phosphorylase b kinase deficiency";
var content_f24_41_25237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Phosphorylase b kinase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25237/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25237/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/41/25237/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen serves as the primary source of energy for high-intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review phosphorylase b kinase deficiency (MIM #306000), which is usually an X-linked disorder. There is confusion over the GSD classification of phosphorylase b kinase deficiency, as both numbers VIII and IX have been assigned. An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHOSPHORYLASE b KINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphorylase b kinase (PBK) is required for the activation of phosphorylase by converting the less enzymatically active phosphorylase b to the more active phosphorylase a with a resulting increase in glycogenolysis. PBK also catalyzes the conversion of glycogen synthase from a more to a less active form. Because of these reciprocal changes, glycogen degradation is active when glycogen synthesis is inactive, and vice versa.",
"   </p>",
"   <p>",
"    The enzyme is composed of four separate subunits (alpha, beta, gamma, delta), each encoded by a distinct gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The holoenzyme is made up of four copies of each isoform, for a final complex of 16 subunits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphophorylase b kinase (PBK) deficiency is genetically heterogeneous, with both autosomal recessive and X-linked forms. This has led to inconsistent classification schemes. The disease has been subclassified, depending on the subunit involved. Defects in the alpha subunit account for 75 percent of cases.",
"   </p>",
"   <p>",
"    PBK deficiency has considerable locus and allelic heterogeneity. The majority of cases are the X-linked liver-specific disease, caused by a variety of mutations in the PHKA2 locus at Xp22 and resulting in a defective alpha(L) subunit (liver isoform). A common cause of hepatic PBK deficiency in Dutch patients is the missense mutation p.Pro1205Leu in the PHKA2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mutation type in patients with disease isolated to the liver appears to correlate with clinical severity. Red blood cell enzyme activity is preserved with hypomorphic mutations and lost with more severe loss of function mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/4\">",
"     4",
"    </a>",
"    ]. Rarely, carrier females manifest clinical features.",
"   </p>",
"   <p>",
"    Mutations in the beta subunit gene (PHKB) located at 16q12 have been described in patients with combined liver and muscle deficiency (GSD IXb) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Autosomal liver disease is caused by mutation of the catalytic gamma subunit encoded by the PHKG2 gene at 16p12 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These patients risk a more severe fibrotic liver disease, in addition to symptoms of hypoglycemia. Muscle-specific disease is caused by mutations in the muscle-specific alpha(M) subunit (PHKA1) located at Xq13 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. To date, six patients have been described, generally with modest elevation of blood creatine phosphokinase (CPK) and variable degrees of exercise intolerance. One patient had cognitive impairment but no evidence of myopathy, and it was suggested that there is a central nervous system function for this subunit, which is known to be expressed in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No mutations in the genes encoding the muscle-specific gamma (PHKG1) and delta (PHKD; CALM1) subunits have been described in myopathic patients with PBK deficiency. CALM1 mutations have been reported in individuals experiencing catecholaminergic polymorphic ventricular tachycardia (CPVT) and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of phosphorylase kinase deficiency are mild. They typically present in early childhood with growth retardation and hepatomegaly, sometimes with hypoglycemia. Unlike some other GSDs affecting the liver, the response to glucagon is normal.",
"   </p>",
"   <p>",
"    In a longitudinal study of 41 patients with phosphorylase kinase deficiency, the following features were described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatomegaly &mdash; 92 percent",
"     </li>",
"     <li>",
"      Growth retardation &mdash; 68 percent",
"     </li>",
"     <li>",
"      Delayed motor development &mdash; 52 percent",
"     </li>",
"     <li>",
"      Hypercholesterolemia &mdash; 76 percent",
"     </li>",
"     <li>",
"      Hypertriglyceridemia &mdash; 70 percent",
"     </li>",
"     <li>",
"      Elevated glutamate pyruvate transaminase &mdash; 56 percent",
"     </li>",
"     <li>",
"      Fasting hyperketosis &mdash; 44 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The course generally is benign. Symptoms resolve over time so that most adults are asymptomatic. The initial growth retardation is typically followed by a spurt of growth that results in a final height that is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other presentations of phosphorylase kinase deficiency include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myopathy, which presents primarily with exercise intolerance, cramps, myalgias, weakness in exercising muscles, myoglobinuria, and, in rare cases, hypotonia in young children; in older individuals, progressive distal weakness is more prominent than proximal weakness [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/10,16-19\">",
"       10,16-19",
"      </a>",
"      ]. This myopathic form has autosomal or X-linked inheritance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.) Only five patients with mutations in the X-linked PHKA1 gene have been reported thus far, and all presented with myopathic symptoms. However, a 17-year&ndash;old patient with a new PHKA1 gene mutation presented with cognitive impairment (&ldquo;borderline&rdquo; mental retardation) but no signs of overt myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fatal infantile cardiomyopathy has been described in children [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. However, heterozygous activating mutations in the gamma-2 subunit of AMP activated protein kinase (PRKAG2) have been described in patients previously reported to have infantile-onset phosphorylase kinase deficiency (\"pseudo PHK deficiency\") [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Adults with unclassified muscle glycogenosis and cardiac involvement with conduction abnormalities may harbor similar point mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H17#H17\">",
"       \"Genetics of hypertrophic cardiomyopathy\", section on 'PRKAG2 and LAMP2 genes and WPW syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=see_link&amp;anchor=H13#H13\">",
"       \"Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy\", section on 'Preexcitation syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The liver and muscle disease subtype is characterized by liver enlargement and nonprogressive muscle disease in childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with the autosomal recessive liver-specific type may develop cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fetal onset has been described in a premature female newborn with history of diminished fetal movements, hypotonia at birth, absent spontaneous movements, increased flexor tone in the extremities, lack of psychomotor development, and death at two months due to central apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/27\">",
"       27",
"      </a>",
"      ]. No hypoglycemic episodes were documented, and myocardial function was normal. While muscle biopsy and enzymatic studies were consistent with phosphorylase b kinase deficiency, molecular confirmation of the diagnosis is missing in this case.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is confirmed by reduced or absent phosphorylase kinase activity in the affected tissue, either liver or muscle. The challenges of enzyme testing and need for DNA testing have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients with the muscle involvement typically have elevated serum creatine kinase activity. If the liver is affected, biopsy reveals excessive glycogen accumulation. The rosettes have a less compact appearance than in other liver glycogenoses. Hepatic fibrosis may be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Forearm ischemic exercise test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In affected individuals, the forearm ischemic exercise test (FIET) reveals a normal or only partially impaired rise of venous lactate levels; this finding is probably related to incomplete PBK deficiency resulting either from the activation of the residual enzyme by calcium or cAMP-dependent protein kinase or the direct activation of phosphorylase b by exercise-increased inosine monophosphate or inorganic phosphorous metabolites. In an adult patient with X-linked phosphorylase b kinase deficiency, there was a normal lactate response during FIET. However, during 60 percent of maximal exercise, there was no increase in blood lactate compared with fourfold increase in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/29\">",
"     29",
"    </a>",
"    ]. The different response of lactate to submaximal aerobic and maximal anaerobic exercise suggests differential activation mechanisms for phosphorylase b kinase under these circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle biopsy is usually normal or reveals subsarcolemmal accumulation of glycogen, primarily in type 2B fibers. The glycogen particles appear free and structurally normal by electron microscopy. Quantitation of muscle glycogen reveals either normal or slightly increased amounts. Immunohistochemical study of frozen muscle sections for phosphorylase is normal, and biochemical determination of PBK activity in muscle reveals either total absence or markedly decreased activity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25237/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for this disorder. Carbohydrate-rich feedings should be provided in patients with hypoglycemia. Nighttime cornstarch can be used as a slowly absorbed form of glucose. Patients should be monitored for progressive liver disease, particularly in the autosomal form.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phosphorylase b kinase (PBK) converts phosphorylase b (less active) to phosphorylase a (more active) with a resulting increase in glycogenolysis. PBK also catalyzes the conversion of glycogen synthase from a more to a less active form. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Phosphorylase b kinase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PBK deficiency is genetically heterogeneous, with both autosomal recessive and X-linked forms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of phosphorylase kinase deficiency are mild. They typically present in early childhood with growth retardation and hepatomegaly, sometimes with hypoglycemia; the response to glucagon is normal. Symptoms generally resolve over time so that most adults are asymptomatic. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is confirmed by reduced or absent phosphorylase kinase activity in the affected tissue, either liver or muscle. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific therapy for PBK deficiency. Carbohydrate-rich feedings should be provided in patients with hypoglycemia. Patients should be monitored for progressive liver disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1994. p.1554.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/2\">",
"      Jones TA, da Cruz e Silva EF, Spurr NK, et al. Localisation of the gene encoding the catalytic gamma subunit of phosphorylase kinase to human chromosome bands 7p12-q21. Biochim Biophys Acta 1990; 1048:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/3\">",
"      Achouitar S, Goldstein JL, Mohamed M, et al. Common mutation in the PHKA2 gene with variable phenotype in patients with liver phosphorylase b kinase deficiency. Mol Genet Metab 2011; 104:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/4\">",
"      Burwinkel B, Shin YS, Bakker HD, et al. Mutation hotspots in the PHKA2 gene in X-linked liver glycogenosis due to phosphorylase kinase deficiency with atypical activity in blood cells (XLG2). Hum Mol Genet 1996; 5:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/5\">",
"      Burwinkel B, Maichele AJ, Aagenaes O, et al. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB). Hum Mol Genet 1997; 6:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/6\">",
"      Francke U, Darras BT, Zander NF, Kilimann MW. Assignment of human genes for phosphorylase kinase subunits alpha (PHKA) to Xq12-q13 and beta (PHKB) to 16q12-q13. Am J Hum Genet 1989; 45:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/7\">",
"      Maichele AJ, Burwinkel B, Maire I, et al. Mutations in the testis/liver isoform of the phosphorylase kinase gamma subunit (PHKG2) cause autosomal liver glycogenosis in the gsd rat and in humans. Nat Genet 1996; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/8\">",
"      Burwinkel B, Rootwelt T, Kvittingen EA, et al. Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene. Pediatr Res 2003; 54:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/9\">",
"      Wehner M, Clemens PR, Engel AG, Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet 1994; 3:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/10\">",
"      Bak H, Cordato D, Carey WF, Milder D. Adult-onset exercise intolerance due to phosphorylase b kinase deficiency. J Clin Neurosci 2001; 8:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/11\">",
"      Echaniz-Laguna A, Akman HO, Mohr M, et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord 2010; 20:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/12\">",
"      Nyegaard M, Overgaard MT, S&oslash;ndergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/13\">",
"      Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013; 127:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/14\">",
"      Willems PJ, Gerver WJ, Berger R, Fernandes J. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr 1990; 149:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/15\">",
"      Schippers HM, Smit GP, Rake JP, Visser G. Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis 2003; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/16\">",
"      Wuyts W, Reyniers E, Ceuterick C, et al. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A 2005; 133A:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/17\">",
"      Abarbanel JM, Bashan N, Potashnik R, et al. Adult muscle phosphorylase \"b\" kinase deficiency. Neurology 1986; 36:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/18\">",
"      Van den Berg IE, Berger R. Phosphorylase b kinase deficiency in man: a review. J Inherit Metab Dis 1990; 13:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/19\">",
"      Clemens PR, Yamamoto M, Engel AG. Adult phosphorylase b kinase deficiency. Ann Neurol 1990; 28:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/20\">",
"      Servidei S, Metlay LA, Chodosh J, DiMauro S. Fatal infantile cardiopathy caused by phosphorylase b kinase deficiency. J Pediatr 1988; 113:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/21\">",
"      Regalado JJ, Rodriguez MM, Ferrer PL. Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency. Pediatr Cardiol 1999; 20:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/22\">",
"      Burwinkel B, Scott JW, B&uuml;hrer C, et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 2005; 76:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/23\">",
"      Akman HO, Sampayo JN, Ross FA, et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase. Pediatr Res 2007; 62:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/24\">",
"      Lafor&ecirc;t P, Richard P, Said MA, et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 2006; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/25\">",
"      Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/26\">",
"      Burwinkel B, Shiomi S, Al Zaben A, Kilimann MW. Liver glycogenosis due to phosphorylase kinase deficiency: PHKG2 gene structure and mutations associated with cirrhosis. Hum Mol Genet 1998; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/27\">",
"      B&uuml;hrer C, van Landeghem F, Br&uuml;ck W, et al. Fetal-onset severe skeletal muscle glycogenosis associated with phosphorylase-b kinase deficiency. Neuropediatrics 2000; 31:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/28\">",
"      Beauchamp NJ, Dalton A, Ramaswami U, et al. Glycogen storage disease type IX: High variability in clinical phenotype. Mol Genet Metab 2007; 92:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25237/abstract/29\">",
"      &Oslash;rngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008; 70:1876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2908 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25237=[""].join("\n");
var outline_f24_41_25237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHOSPHORYLASE b KINASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Forearm ischemic exercise test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2908|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28199?source=related_link\">",
"      Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_41_25238="Triclonal pattern immunofix";
var content_f24_41_25238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Triclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the immunofixation pattern of a single serum specimen with antisera to heavy chain determinants of IgA, IgG, and IgM, and to kappa and lambda light chain determinants. It shows a discrete IgG band and a discrete kappa band with similar mobility, indicative of an IgG kappa monoclonal protein. There are also IgA lambda and IgM kappa monoclonal proteins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25238=[""].join("\n");
var outline_f24_41_25238=null;
var title_f24_41_25239="Basic principles and technique of bronchoalveolar lavage";
var content_f24_41_25239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles and technique of bronchoalveolar lavage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25239/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/41/25239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL), performed during flexible fiberoptic bronchoscopy, has gained widespread acceptance as a minimally invasive method that provides important information about immunologic, inflammatory, and infectious processes taking place at the alveolar level. Studies comparing BAL cellular constituents to cells obtained from open lung biopsy have shown that the cell types and their state of activation are similar with either collection method.",
"   </p>",
"   <p>",
"    This review will consider the basic principles and technique of BAL. The utility of this procedure in individual diseases is discussed in the appropriate topic reviews. The use of preprocedure medication, topical anesthesia of the upper airway, and techniques for the passage of the bronchoscope into the lung are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL has been widely used in patients with a variety of lung diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ]. Advantages with this technique include its noninvasive nature and ability to readily sample alveolar contents.",
"   </p>",
"   <p>",
"    As a result, it has an important role in management of diffuse lung diseases for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is an excellent method to obtain specimens to rule out opportunistic infections in immunocompromised hosts.",
"     </li>",
"     <li>",
"      It can provide clues to the correct diagnosis of certain diseases (eg, acute eosinophilic pneumonia and diffuse alveolar hemorrhage). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"       \"Idiopathic acute eosinophilic pneumonia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some cases, it permits assessment of the stage of disease and potential responsiveness to therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no absolute contraindications to the performance of BAL beyond those commonly associated with bronchoscopy (",
"    <a class=\"graphic graphic_table graphicRef79205 \" href=\"UTD.htm?18/7/18555\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. BAL is usually well tolerated; rarely, it is complicated by transient hypoxemia due to residual fluid in the alveoli. Thus, oxygen saturation should be assessed continuously, and all patients should breathe supplemental oxygen during the procedure, titrated to maintain the oxygen saturation above 92 percent. In patients with borderline oxygenation, elective preprocedure intubation and ventilation during the procedure should be considered, as oxygenation will likely deteriorate during the BAL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL is performed following general inspection of the tracheobronchial tree and before biopsy or brushing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ]. This sequence minimizes the likelihood that iatrogenic bleeding will alter the concentration of cellular and protein components. The usual procedures for patient preparation, sedation, and monitoring for fiberoptic bronchoscopy should be followed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BAL differs from bronchial washings, in which secretions are aspirated from large airways directly or following the instillation of 10 to 30 mL of saline.",
"   </p>",
"   <p>",
"    Whole lung lavage is a different procedure that is uniquely used as therapy for pulmonary alveolar proteinosis; 30 to 50 liters of sterile saline are delivered via a double lumen endotracheal tube under general anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Optimal site",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information exists regarding the optimal site in the lung for BAL, although a good general rule is to perform the lavage where the disease is most prominent radiographically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ]. In localized disease, lavage of the involved segment is more likely to yield the best results. In diffuse disease, the right middle lobe or lingula is lavaged most commonly because, when the patient is supine, the anatomy favors maximal recovery of fluid and cells from these sites. If anatomic or technical difficulties are encountered, either the superior or anterior segment of a lower lobe may be used.",
"   </p>",
"   <p>",
"    Lavage in one site is usually adequate, especially if a cumulative volume of 100 mL or greater is instilled. A lavage volume of 100 mL samples approximately one million alveoli (1.5 to 3 percent of the lung). It is thought that such a sample provides a representative picture of the inflammatory and immune processes in the alveoli regardless of the site of the lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/6\">",
"     6",
"    </a>",
"    ]. Nevertheless, some centers routinely instill 100 mL of fluid into each of two or three different areas. Such an approach may be particularly useful when there is marked radiographic heterogeneity in the disease process. The lavage site(s) should always be recorded in the bronchoscopy report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluid instillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the site has been chosen, the bronchoscope is advanced into a subsegmental bronchus until the lumen is occluded; this is referred to as the \"wedged\" position. Care must be taken to avoid \"over wedging\" the bronchoscope, since this can result in additional trauma to the airway and diminish fluid recovery. A good wedge position is usually confirmed by noting slight airway collapse when gentle suction is applied. A poor wedge position allows leakage of lavage fluid around the bronchoscope, leading to cough soon after the fluid is instilled. Optimum fluid recovery occurs when the bronchoscope completely occludes the bronchial lumen of a 3rd or 4th bronchial subsegment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sterile buffered or unbuffered saline (commercial 0.9 percent NaCl without additives for intravenous use) is used as the instillate. Prewarming the lavage fluid to 37&ordm;C has been suggested to decrease coughing and to increase the cellular yield, but most groups continue to use room temperature saline.",
"   </p>",
"   <p>",
"    The total volume of fluid to be instilled has not been standardized. BAL typically involves the delivery of a total of 100 to 240 mL of fluid in 20 to 60 mL aliquots; larger volumes are occasionally used for research purposes. We usually use two to three sequential aliquots of 40 to 60 mL each. Using tubing with an inline clamp or three way stopcock, a saline-filled, 50 to 60 mL syringe is attached to the side port of the bronchoscope. The first aliquot of saline is instilled slowly and steadily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluid recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the first aliquot of saline is infused, it is recovered immediately into the same syringe by gentle continuous hand suction. Suction should be gentle enough that visible airway collapse does not occur. In patients with marked airway collapse despite gentle suction, the suctioning process should be slower, and discontinuous suction should be used to maximize fluid retrieval. When no further fluid can be aspirated, the clamp or stopcock is closed and the syringe (but not the tubing) removed. The second saline filled syringe is attached to the tubing and the procedure repeated. Following these steps, a third lavage is completed, if desired.",
"   </p>",
"   <p>",
"    In patients with suspected alveolar hemorrhage, three sequential lavages are performed at the same site. The recovered samples are visually inspected for any increase in hemorrhagic appearance from the first syringe to the third. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternate methods of fluid recovery include allowing the lavage fluid to flow out by gravity into a dependent flask and using gentle wall suction into a fluid trap.",
"   </p>",
"   <p>",
"    There is no established",
"    <strong>",
"     dwell time",
"    </strong>",
"    for the fluid to remain before it is suctioned back. We feel that the cellular and noncellular yield is improved by having the patient take several breaths before the fluid is retrieved, though some have raised concern about breaking the wedged position by adding this step. The total duration of lavage after wedging the bronchoscope should take approximately 5 to 10 minutes.",
"   </p>",
"   <p>",
"    Lavage fluid recovery is influenced by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It increases with larger volumes instilled. The first aliquot of fluid tends to be poorly recovered (&lt;20 percent); with subsequent aliquots, the return increases, such that 40 to 70 percent of the total instilled volume is recovered.",
"     </li>",
"     <li>",
"      Small instilled volumes (less than 100 mL) increase the likelihood of contamination of lavage fluid by mucus and large airway cells, rather than sampling of distal (alveolar) sites.",
"     </li>",
"     <li>",
"      A history of current or past smoking or the presence of chronic obstructive pulmonary disease (COPD) significantly decreases the fluid recovery rate [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/7\">",
"       7",
"      </a>",
"      ]. The average BAL fluid recovery in normal healthy nonsmokers is between 50 to 80 percent of the instilled volume, compared with recovery as low as 20 to 30 percent in otherwise healthy smokers.",
"     </li>",
"     <li>",
"      Fluid recovery decreases with increasing age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lavage procedure should be terminated if the instilled volume exceeds recovery by more than 100 mL, or if the patient experiences substantial distress (eg, excessive coughing) or falling oxygen saturation requiring increased oxygen supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROCESSING THE LAVAGE SPECIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recovered lavage fluid should be pooled into a single container (siliconized glass or non-cell adherent plastic) and the total volume measured. Controversy exists about whether to include the first aliquot of fluid recovered with the remainder; this is more of an issue when the specimen is being processed for cell counts in patients with interstitial lung disease than when evaluating for infection. The first aliquot is usually a small volume and represents a disproportionate amount of bronchial airway material (epithelial cells and neutrophils) compared to alveolar fluid. Our practice is to pool all of the recovered BAL fluid and to ensure that the pooled fluid is well-mixed.",
"   </p>",
"   <p>",
"    BAL fluid generally should be transported to the laboratory on ice, but can be stored or transported at room temperature if processing will occur in less than one hour. Cells in BAL fluid remain viable for up to four hours when stored at 25&ordm;C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CELL COUNTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell counting of BAL fluid is useful in the evaluation of certain interstitial lung diseases, such as the eosinophilic pneumonias, hypersensitivity pneumonitis, sarcoidosis, and drug-induced lung disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initial processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of steps are involved in the optimal processing and examination of BAL samples. The lavage fluid frequently contains large amounts of mucus. When cell counts will be performed in the evaluation of interstitial lung disease, filtration of the fluid through sterile cotton gauze or nylon mesh is often performed to prevent the mixing of mucus with the cell pellet after centrifugation; filtration also results in the preferential removal of bronchial epithelial cells. An aliquot of the fluid and cells should be stored in case future testing is required.",
"   </p>",
"   <p>",
"    When clinically appropriate (eg, suspicion of Langerhans cell histiocytosis), approximately three million cells should be fixed in cacodylate buffered glutaraldehyde (at a concentration of 2.5 percent for 1 hour at 4&ordm;C) for electron microscopic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Total cell counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total number of leukocytes recovered by lavage is determined by examination of a sample of the pooled fluid with a hemocytometer. The cell counts are most accurate when done on the original, pooled sample before any washing procedure has been performed; washing results in a loss of total cells and a decrease in the cell viability.",
"   </p>",
"   <p>",
"    The total white cell count is usually expressed both as the total number of cells recovered per lavage and as the concentration of cells per mL of recovered fluid. Red blood cells and epithelial cells should be enumerated, but are not included in the total white cell count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential cell counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential cell counts are most frequently determined on slides prepared either by cytocentrifugation or filtration. These procedures are operator-dependent and should be performed by an experienced and properly trained cytotechnologist.",
"   </p>",
"   <p>",
"    With either technique, at least 8 to 10 slides are prepared. The differential counts are performed with a light microscope employing 25x and 40x objectives. Counts are made from random fields of 200 to 500 cells. Esterase staining is often employed to distinguish immature macrophages from large lymphocytes. The number of ciliated or squamous epithelial cells should be noted, but they are not included in the differential count.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytocentrifugation &mdash; Cytocentrifugation is the more commonly used method for obtaining a differential cell count; as the name implies, it collects cells by virtue of their outward migration when centrifuged [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/8\">",
"       8",
"      </a>",
"      ]. Differential counting is commonly performed on air-dried (15 to 30 minutes) May-Grunwald-Giemsa or Wright-Giemsa stained preparations. The specimens have less distortion of cell structure and less cell loss (especially the selective loss of lymphocytes) when the \"neat\" fluid, ie, the original sample before centrifugation and resuspension, is used for the cytocentrifuge preparation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advantages of this technique include lower cost than filtration methods and the fact that cytocentrifugation slides permit detection of more subtle cytologic features which can occasionally aid diagnosis. Special stains for iron, inorganic dust, malignant cells, and microorganisms may be performed if desired.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Filtration &mdash; With the filtration method, differential cell counts are performed after trapping cells on a filter. The cells are then stained with hematoxylin and eosin or the modified Papanicolaou technique [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/9\">",
"       9",
"      </a>",
"      ]. This method offers two advantages. First, cell retention by the filter is high, providing a more accurate representation of the cell types and numbers recovered by lavage. Second, these slides can be stored indefinitely without significant loss of cell detail or staining. The major disadvantages of the filter preparations are that they may underestimate the number of neutrophils, and that the method is considerably more time consuming and costly than cytocentrifuge preparation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adequacy of BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clear criteria exist for determining the adequacy of the BAL specimen. Unsatisfactory specimens for cell counts for evaluating interstitial lung disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contain fewer than two million total cells",
"     </li>",
"     <li>",
"      Have fewer than 10 alveolar macrophages per high power field",
"     </li>",
"     <li>",
"      Contain excessive numbers of epithelial cells, either showing morphologic degenerative changes or exceeding the number of alveolar macrophages present",
"     </li>",
"     <li>",
"      Contain a mucopurulent exudate of polymorphonuclear cells",
"     </li>",
"     <li>",
"      Contain excessive red blood cells due to trauma during the procedure",
"     </li>",
"     <li>",
"      Contain degenerative changes or laboratory artifacts obscuring cell identity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Data expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common method is to present cell differential data in the same manner used for peripheral blood, ie, each white cell type is given as a percentage of the total white cells recovered. The advantage of this method is that it provides the data in a fashion that is familiar. A disadvantage is that the numbers presented are proportions of the total and, as such, changes in the absolute numbers of a single cell line necessarily affect the reported percentages of all cell lines.",
"   </p>",
"   <p>",
"    With the total cell method, the differential is combined with the total cell count to quantify the absolute numbers of each cell type per volume of fluid recovered. The advantage of this method is that it also gives insight into the total number of effector cells present in the alveolar structures. Unfortunately, such quantification is most meaningful if standardized lavage volumes are instilled and recovered. At present, such standardization is not possible, and the differential percentage count of total BAL cells is the more commonly used approach. However, until clear standards are established, both methods should be used and reported by the cytology laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Noncellular components of BAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of routine measurement of the noncellular components of BAL in clinical practice remains to be elucidated. It has been extremely difficult to determine what proportion of the fluid recovered by lavage represents alveolar fluid from the distal airways and alveoli, so-called epithelial lining fluid (ELF). Several approaches have been proposed to determine the volume of epithelial lining fluid recovered by BAL, including quantitation of albumin, total lavage protein, potassium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , and urea. However, none of these has become standard practice. In the future, proteomic analysis of ELF may become an attractive method to examine for changes in protein expression and secretion during the course of pulmonary disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunofluorescence and immunocytochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of immunofluorescent and immunocytochemical techniques to the analysis of cells recovered from BAL has predominantly been confined to research laboratories. Immunohistochemistry is helpful in the diagnosis of certain interstitial lung diseases and pulmonary lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphocyte subpopulations (eg, CD3, CD4, CD8) can be assessed using immunofluorescent labeled monoclonal antibodies. After incubation with these antibodies, the cells can be passed through a flow cytometer for counting and assessment of polyclonality. The CD4 to CD8 ratio can then be calculated. The advantage of flow cytometry over hand counting of immunohistochemical stained cells on cytocentrifuge prepared slides is the greater number of cells counted by flow cytometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NORMAL BAL CELL COUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;BAL performed in healthy volunteers has permitted determination of the normal composition of BAL fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/1\">",
"     1",
"    </a>",
"    ]. The average number of cells recovered in healthy nonsmoking adults ranges from approximately 100 to 150 thousand per mL of lavage fluid recovered. The proportions of the different cell types in normal nonsmoking adults are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef50382 \" href=\"UTD.htm?30/4/30797\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking increases the number of cells recovered by a factor of four to six, largely due to an increase in the number of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/15\">",
"     15",
"    </a>",
"    ]. Additional changes in the cell populations are associated with smoking as noted in the tables: never smokers (",
"    <a class=\"graphic graphic_table graphicRef50382 \" href=\"UTD.htm?30/4/30797\">",
"     table 2",
"    </a>",
"    ); former smokers (",
"    <a class=\"graphic graphic_table graphicRef71367 \" href=\"UTD.htm?30/20/31053\">",
"     table 3",
"    </a>",
"    ); and current smokers (",
"    <a class=\"graphic graphic_table graphicRef66165 \" href=\"UTD.htm?29/63/30717\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the clinical situation, samples may be sent for a variety of microbiologic analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/16\">",
"     16",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine qualitative or quantitative bacterial culture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link&amp;anchor=H322748#H322748\">",
"       \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Respiratory culture'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Direct fluorescent antigen (DFA) testing for Legionella species (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Legionella infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Legionella culture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Legionella infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycobacterial, fungal, and viral culture",
"     </li>",
"     <li>",
"      Shell vial immunohistochemical assay or direct staining of BAL macrophages with monoclonal antibodies for cytomegalovirus pneumonia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of cytomegalovirus\", section on 'Early antigen detection'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fluorescent or silver stain for Pneumocystis jirovecii. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"       \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CYTOLOGIC ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologic analysis of BAL fluid may be helpful in evaluating some lung malignancies (eg, lymphangitic carcinomatosis) and diffuse lung diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After pooling of the total recovered lavage fluid (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Processing the lavage specimen'",
"    </a>",
"    above), a sample is removed and placed in cytology preservative solution and transported to the cytology laboratory. Papanicolaou staining is typically used for detecting tumor cells and viral inclusion bodies; periodic acid-Schiff (PAS) staining to identify PAS-positive lipoproteinaceous material in the distal air spaces and macrophages; and Prussian blue staining for hemosiderin to detect macrophages that have taken up red cells during chronic bleeding, as in diffuse alveolar hemorrhage. When greater than 20 percent of 200 macrophages stain positive for hemosiderin, a diagnosis of diffuse alveolar hemorrhage is usually made [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible fiberoptic bronchoscopy with bronchoalveolar lavage is usually well tolerated. Rarely, BAL is complicated by fever, bronchoconstriction, transient hypoxemia or pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25239/abstract/4,5,24\">",
"     4,5,24",
"    </a>",
"    ]. However, pneumothorax is rare enough that postprocedure chest radiographs are usually not obtained unless the clinical status of the patient has deteriorated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=see_link&amp;anchor=H12562876#H12562876\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoalveolar lavage (BAL), performed during fiberoptic bronchoscopy, is a minimally invasive technique for evaluating the immunologic, inflammatory, and infectious processes taking place at the alveolar level in diffuse lung disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BAL is an excellent technique for evaluating opportunistic infections in immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications to the performance of BAL beyond those commonly associated with bronchoscopy (",
"      <a class=\"graphic graphic_table graphicRef79205 \" href=\"UTD.htm?18/7/18555\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In localized disease, lavage of the involved segment is most likely to yield the best results. In diffuse disease, the right middle lobe or lingula is often chosen to optimize fluid recovery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The total volume of fluid to be instilled during BAL has not been standardized. We usually use two to three sequential aliquots of 40 to 60 mL each. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid instillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of steps are involved in the optimal processing and examination of BAL samples for total and differential cell counting. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cell counting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphocyte subpopulations (eg, CD3, CD4, CD8) can be assessed using immunofluorescent labeled monoclonal antibodies and either flow cytometry or hand counting of a slide from a cytocentrifuge specimen. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Immunofluorescence and immunocytochemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending on the clinical situation, samples of BAL fluid may be sent for a variety of microbiologic analyses, including bacterial, viral and fungal cultures, and also direct fluorescent antigen (DFA) staining for Legionella or Pneumocystis jirovecii. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Microbiologic analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytology of BAL fluid may be of use in the evaluation of some diffuse neoplasms affecting the lung (eg, bronchoalveolar carcinoma, lymphangitic carcinomatosis, and lymphoma) and in the evaluation of some diffuse lung diseases (eg, pulmonary alveolar proteinosis). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cytologic analysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     King TE Jr. Handling and analysis of bronchoalveolar lavage specimens. In: Bronchoalveolar Lavage, Baughman RP (Ed), Year Book Medical Publishers, Philadelphia 1991. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/2\">",
"      Stoller JK, Rankin JA, Reynolds HY. The impact of bronchoalveolar lavage cell analysis on clinicians' diagnostic reasoning about interstitial lung disease. Chest 1987; 92:839.",
"     </a>",
"    </li>",
"    <li>",
"     King, TE Jr. Interstitial lung disease. In: Feinsilver, SH, Fein, AM (Eds), Textbook of Bronchoscopy, Williams &amp; Wilkins, Baltimore, 1995, p. 185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/4\">",
"      Elston WJ, Whittaker AJ, Khan LN, et al. Safety of research bronchoscopy, biopsy and bronchoalveolar lavage in asthma. Eur Respir J 2004; 24:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/5\">",
"      Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med 2007; 28:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/6\">",
"      Helmers RA, Dayton CS, Floerchinger C, Hunninghake GW. Bronchoalveolar lavage in interstitial lung disease: effect of volume of fluid infused. J Appl Physiol 1989; 67:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/7\">",
"      L&ouml;fdahl JM, Cederlund K, Nathell L, et al. Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysema. Eur Respir J 2005; 25:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/8\">",
"      Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/9\">",
"      Chou CW, Lin FC, Tung SM, et al. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/10\">",
"      Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005; 5:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/11\">",
"      Fietta A, Bardoni A, Salvini R, et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res Ther 2006; 8:R160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/12\">",
"      Harbeck RJ. Immunophenotyping of bronchoalveolar lavage lymphocytes. Clin Diagn Lab Immunol 1998; 5:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/13\">",
"      Welker L, J&ouml;rres RA, Costabel U, Magnussen H. Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004; 24:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/14\">",
"      Smith PA, Kohli LM, Wood KL, et al. Cytometric analysis of BAL T cells labeled with a standardized antibody cocktail correlates with immunohistochemical staining. Cytometry B Clin Cytom 2006; 70:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/15\">",
"      Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141:S169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/16\">",
"      Chang GC, Wu CL, Pan SH, et al. The diagnosis of pneumonia in renal transplant recipients using invasive and noninvasive procedures. Chest 2004; 125:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/17\">",
"      Zompi S, Couderc LJ, Cadranel J, et al. Clonality analysis of alveolar B lymphocytes contributes to the diagnostic strategy in clinical suspicion of pulmonary lymphoma. Blood 2004; 103:3208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/18\">",
"      Phadke SM, Chini BA, Patton D, Goyal RK. Relapsed non-Hodgkin's lymphoma diagnosed by flexible bronchoscopy. Pediatr Pulmonol 2002; 34:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/19\">",
"      Poletti V, Romagna M, Allen KA, et al. Bronchoalveolar lavage in the diagnosis of disseminated lung tumors. Acta Cytol 1995; 39:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/20\">",
"      Lower EE, Baughman RP. Pulmonary lymphangitic metastasis from breast cancer. Lymphocytic alveolitis is associated with favorable prognosis. Chest 1992; 102:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/21\">",
"      Levy H, Horak DA, Lewis MI. The value of bronchial washings and bronchoalveolar lavage in the diagnosis of lymphangitic carcinomatosis. Chest 1988; 94:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/22\">",
"      Maldonado F, Parambil JG, Yi ES, et al. Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J 2009; 33:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/23\">",
"      De Lassence A, Fleury-Feith J, Escudier E, et al. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995; 151:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25239/abstract/24\">",
"      Jain P, Sandur S, Meli Y, et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125:712.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4303 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25239=[""].join("\n");
var outline_f24_41_25239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Optimal site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluid instillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluid recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROCESSING THE LAVAGE SPECIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CELL COUNTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initial processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Total cell counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential cell counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adequacy of BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Data expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Noncellular components of BAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunofluorescence and immunocytochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NORMAL BAL CELL COUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MICROBIOLOGIC ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CYTOLOGIC ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4303\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4303|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/7/18555\" title=\"table 1\">",
"      Contraindications bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/4/30797\" title=\"table 2\">",
"      BAL fluid in non smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/20/31053\" title=\"table 3\">",
"      BAL fluid in former smokers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/63/30717\" title=\"table 4\">",
"      BAL fluid in smokers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38199?source=related_link\">",
"      Clinical manifestations and diagnosis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=related_link\">",
"      Diagnosis and treatment of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_41_25240="Diflunisal: Drug information";
var content_f24_41_25240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diflunisal: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41493?source=see_link\">",
"    see \"Diflunisal: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diflunisal&reg;;",
"     </li>",
"     <li>",
"      Novo-Diflunisal;",
"     </li>",
"     <li>",
"      Nu-Diflunisal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate pain:",
"     </b>",
"     Oral: Initial: 500-1000 mg followed by 250-500 mg every 8-12 hours; maximum daily dose: 1.5 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arthritis:",
"     </b>",
"     Oral: 500-1000 mg/day in 2 divided doses; maximum daily dose: 1.5 g",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F159986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use with caution; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Administer 50% of normal dose (Aronoff, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: No supplement required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CAPD: No supplement require",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CAVH: Dose for GFR 10-50",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F159959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablet should be swallowed whole; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory disorders usually including rheumatoid arthritis and osteoarthritis; can be used as an analgesic for treatment of mild-to-moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13934205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 9%), dizziness (1% to 3%), insomnia (1% to 3%), somnolence (1% to 3%), fatigue (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 9%), dyspepsia (3% to 9%), GI pain (3% to 9%), diarrhea (3% to 9%), constipation (1% to 3%), flatulence (1% to 3%), vomiting (1% to 3%), GI ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute anaphylactic reaction, agranulocytosis, allergic reactions, angioedema, anorexia, blurred vision, bronchospasm, confusion, chest pain, cholestasis, cystitis, depression, diaphoresis, disorientation, dry mucous membranes, dyspnea, dysuria, edema, eructation, erythema multiforme, esophagitis, exfoliative dermatitis, flushing, gastritis, GI bleeding, GI perforation, hallucinations, hearing decreased, hearing loss, hematuria, hemolytic anemia, hepatitis, hypersensitivity syndrome, hypersensitivity vasculitis, interstitial nephritis, itching, jaundice, mental depression, muscle cramps, necrotizing fasciitis, nephrotic syndrome, nervousness, palpitation, paresthesia, peptic ulcer, peripheral neuropathy, photosensitivity, proteinuria, pruritus, renal impairment, renal failure, seizure, Stevens-Johnson syndrome, stomatitis, syncope, tachycardia, thrombocytopenia, toxic epidermal necrolysis, trembling, urticaria, vasculitis, vertigo, weakness, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diflunisal, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity syndrome: A hypersensitivity syndrome has been reported; monitor for constitutional symptoms and cutaneous findings; other organ dysfunction may be involved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reye's syndrome: Diflunisal is a derivative of acetylsalicylic acid and therefore may be associated with Reye&rsquo;s syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1624554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies diflunisal as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9516955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diflunisal is excreted into breast milk at levels of 2% to 7% of those in maternal plasma. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F159966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food to decrease GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diflunisal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $154.95",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Analeric (GR);",
"     </li>",
"     <li>",
"      Ansal (NZ);",
"     </li>",
"     <li>",
"      Anton (TW);",
"     </li>",
"     <li>",
"      Cleating (CL);",
"     </li>",
"     <li>",
"      Dialon (ID);",
"     </li>",
"     <li>",
"      Diflonid (NO);",
"     </li>",
"     <li>",
"      Dolobid (BF, BJ, CI, CZ, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PT, RU, SC, SD, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dolocid (NL);",
"     </li>",
"     <li>",
"      Donobid (NO, SE);",
"     </li>",
"     <li>",
"      Flunidor (PT);",
"     </li>",
"     <li>",
"      Ilacen (TW);",
"     </li>",
"     <li>",
"      Senta (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees) include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic: ~1 hour; maximal effect: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.11 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; metabolic pathways are saturable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8-12 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~3% as unchanged drug, 90% as glucuronide conjugates) within 72-96 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arias J, Fernandez-Rivas M, Moral A, et al, &ldquo;Selective Adverse Reactions to Diflunisal,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 1995, 74(2):160-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/7697476/pubmed\" id=\"7697476\" target=\"_blank\">",
"        7697476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Berns JS, Brier ME, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults",
"      </i>",
"      , 4th ed. Philadelphia, PA: American College of Physicians; 1999, p 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balali-Mood M and Prescott LF, &ldquo;Failure of Alkaline Diuresis to Enhance Diflunisal Elimination,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1980, 10(2):163-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/7426277/pubmed\" id=\"7426277\" target=\"_blank\">",
"        7426277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs-Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;New Approaches to Preventing and Treating Postoperative Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):26-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1033):79-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/9722804/pubmed\" id=\"9722804\" target=\"_blank\">",
"        9722804",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Butterworth GA, Burchfield WH, et al, &ldquo;A 12-Hour Evaluation of the Analgesic Efficacy of Diflunisal, Zomepirac Sodium, Aspirin, and Placebo in Postoperative Oral Surgery Pain,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1983, 3(2 Pt 2):38S-46S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/6344038/pubmed\" id=\"6344038\" target=\"_blank\">",
"        6344038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Calderazzo JP, Bowser MW, et al, &ldquo;A 12-Hour Evaluation of the Analgesic Efficacy of Diflunisal, Aspirin, and Placebo in Postoperative Dental Pain,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1982, 22(2-3):89-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/7068938/pubmed\" id=\"7068938\" target=\"_blank\">",
"        7068938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gobetti JP, &ldquo;Controlling Dental Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):47-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Upadhyay HP and Gupta SK, &ldquo;Diflunisal (Dolobid&reg;) Overdosage,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1978, 2(6137):640.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/41/25240/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9357 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25240=[""].join("\n");
var outline_f24_41_25240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708697\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159980\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160022\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159984\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159985\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159986\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796066\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159955\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159941\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874606\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159959\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159958\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934205\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160020\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159962\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159945\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159950\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159975\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159952\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1624554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159989\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9516955\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159966\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159965\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159967\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159944\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159961\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41493?source=related_link\">",
"      Diflunisal: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_41_25241="Treatment of uncomplicated falciparum malaria";
var content_f24_41_25241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of uncomplicated falciparum malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/41/25241/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/41/25241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute falciparum malaria presents as a continuum from mild to severe disease; the severity of disease dictates the approach to therapy. Uncomplicated malaria consists of symptomatic malaria parasitemia &lt;5 percent without evidence of vital organ dysfunction, with the ability to take oral therapy. Young children, non-immune adults, and immunocompromised patients with malaria may deteriorate rapidly; the risks of undertreating severe malaria considerably exceed the risks of overtreating uncomplicated malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of uncomplicated malaria consists of oral therapy with a combination of two agents; the goal of this strategy is to forestall the development of further antimalarial resistance and protect the agents that are presently effective. Local antimalarial drug resistance patterns, government treatment guidelines, tolerability, availability, and gametocidal activity guide selection of therapeutic agents.",
"   </p>",
"   <p>",
"    The patterns of resistance to antimalarial chemotherapy and the available options for the treatment of malaria will be reviewed here. The epidemiology, pathogenesis, clinical features, diagnosis, and chemoprophylaxis of malaria are discussed separately, as is treatment of severe falciparum malaria and nonfalciparum malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=see_link\">",
"     \"Epidemiology, prevention, and control of malaria in endemic areas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=see_link\">",
"     \"Pathogenesis of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link\">",
"     \"Treatment of severe falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189103\">",
"    <span class=\"h1\">",
"     MANAGEMENT OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;To establish the diagnosis of malaria, blood smears or a rapid diagnostic test (RDT) should be performed. If the RDT is positive, a smear is important for speciation and to determine degree of parasitemia. If the initial diagnostic evaluation is negative, follow up testing should be done each day for two more days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for hospitalization should be dictated by clinical manifestations and parasite species. Important considerations include evidence of severe clinical manifestations and presence of P. falciparum or P. knowlesi in a non-immune host [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients from non-endemic areas with no acquired immunity are at risk for poor outcome in the setting of P. falciparum or P. knowlesi. In endemic areas acquired immunity may reduce the risk for poor outcome and such patients are often not admitted.",
"   </p>",
"   <p>",
"    Hospitalization permits clinical observation for tolerance of antimalarial therapy, monitoring for falling parasitemia (reflecting efficacy of therapy), and advanced management in the case of progression to severe disease. The approach to selection of antimalarial therapy is discussed in the following sections.",
"   </p>",
"   <p>",
"    Follow up smears to demonstrate declining parasitemia with subsequent clearance is the accepted clinical practice. Occasionally gametocytes can be seen after successful treatment (such as in the case of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    treatment, which does not kill gametocytes). These are not harmful to the patient and clear eventually. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    as a gametocide for reducing transmission is discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients should be informed that malaria can recrudesce, and if they have febrile episodes in the future that repeat evaluation for malaria should be pursued.",
"   </p>",
"   <p>",
"    Malaria is a nationally notifiable disease and all cases should be reported to the state health department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189157\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Chloroquine sensitive malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    sensitive regions include Haiti, the Dominican Republic, most regions of the Mid East, and Central America west of the Panama Canal (",
"    <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"     figure 3",
"    </a>",
"    ). Treatment with chloroquine may be administered to patients for whom chloroquine sensitive P. falciparum malaria can be predicted with certainty. Treatment for chloroquine resistant P. falciparum should be administered in the setting of known exposure to a chloroquine resistant region, uncertain exposure history, or unknown prevalence of chloroquine resistance.",
"   </p>",
"   <p>",
"    Dosing for administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 1",
"    </a>",
"    ). Mechanism and adverse effects of chloroquine are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=see_link\">",
"     \"Antimalarial drugs: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Reversion of chloroquine resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reappearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    sensitive strains has been described in the setting of chloroquine withdrawal for treatment of malaria. In a study of 210 children in Malawi, treatment of uncomplicated malaria with chloroquine was 99 percent effective, 12 years after chloroquine was withdrawn due to resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/3\">",
"     3",
"    </a>",
"    ]. This suggests that in areas where chloroquine regains effectiveness, the use of this drug as a partner in antimalarial combination therapy may be effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chloroquine resistant malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment of uncomplicated malaria due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    resistant P. falciparum consists of one of the following agents (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Artemisinin derivative combinations",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       Atovaquone-proguanil",
"      </a>",
"      (Malarone)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      -based regimen (in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      (Lariam) (in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Artemisinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artemisinin combination therapies (ACTs) are recommended by the WHO as the first line treatment of uncomplicated falciparum malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1\">",
"     1",
"    </a>",
"    ]. They are potent against all developmental stages of the asexual forms of malaria, resulting in the most rapid clearance time relative to other agents. In addition, ACTs also have activity against gametocytes, the stage responsible for continued transmission (",
"    <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"     figure 4",
"    </a>",
"    ). Artemisinin derivatives have the advantage of a low side effect profile, absence of cinchonism, and a significantly reduced incidence of hypoglycemia compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several oral artemisinin derivatives including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    and artemether; these agents are metabolized to the active agent dihydroartemisinin. These compounds differ slightly in their stability, oral absorption, bioavailability, and metabolism. No serious toxicities from artemisinin derivatives have been observed in humans, although neurotoxicity has been reported in animals. Artemisinin derivatives should not be used during the first trimester of pregnancy unless there are no alternatives because of insufficient safety data. Trials to determine artemisinin safety in first trimester are ongoing.",
"   </p>",
"   <p>",
"    Artemisinins should be given in combination to forestall resistance, particularly since this class has a short half life; recrudescence would result if administered alone for a short period. Possible partner drugs in ACT regimens include amodiaquine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , lumefantrine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    , piperaquine, pyronaridine, chlorproguanil-dapsone, proguanil-dapsone, and sulfadoxine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     Artemether-lumefantrine",
"    </a>",
"    is available as a fixed dose combination (Riamet, CoArtem). The half life of the partner drug must be much longer than the artemisinin to prevent recrudescence or new infection with P. falciparum as well as other species [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, no artemisinin-containing combination regimen has been unequivocally proven to be superior to any other. Each combination has variable efficacy in preventing gametocytemia, which mediates transmission (and reinfection) rates in endemic areas. The World Health Organization (WHO) favors the following combinations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      artemether + lumefantrine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      + amodiaquine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      +",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      +",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"       sulfadoxine-pyrimethamine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When used in combination with other drugs, the total artemisinin dose (10 to 12",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is given over three to five days. Treatment regimens should avoid partnering an artemisinin derivative with a drug that has reduced efficacy due to resistance such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Local drug resistance patterns should inform treatment guidelines. In Cambodia, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    should not be used as the artemisinin partner. This was illustrated in a study including 151 patients with uncomplicated falciparum malaria treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    and mefloquine; on days 2 and 3 of therapy, parasitemia persisted in 47 and 11 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/8\">",
"     8",
"    </a>",
"    ]. Similarly, among 261 children in Tanzania, the combination of artesunate plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for uncomplicated malaria resulted in a recrudescence rate of 32 versus 9 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    arm, although the combination is effective for adults in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Validating ACTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 16 randomized trials found that three days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    added to a conventional regimen reduced treatment failure, recrudescence, and gametocyte carriage compared with the conventional regimen alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/12\">",
"     12",
"    </a>",
"    ]. Overall, no artemisinin-containing combination regimen has been unequivocally proven to be superior to any other. The World Health Organization (WHO) favors the combinations outlined in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/13\">",
"     13",
"    </a>",
"    ]. Notable clinical trials evaluating treatment with artemisinin-containing regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       Artemether-lumefantrine",
"      </a>",
"      &mdash; Artemether-lumefantrine is well tolerated with a cure rate &gt;95 percent for P. falciparum in a number of trials as illustrated by the following data [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/14-22\">",
"       14-22",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In Africa, where multidrug resistant P. falciparum is common, a three day (six dose) regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       artemether-lumefantrine",
"      </a>",
"      is effective for the treatment of uncomplicated malaria in children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. This was illustrated in a trial of 1811 children in Tanzania randomized to receive treatment with amodiaquine monotherapy, amodiaquine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"       sulfadoxine-pyrimethamine",
"      </a>",
"      , amodiaquine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      , or artemether-lumefantrine; recrudescence rates were 48, 34, 11 and 3 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 330 patients in Laos with uncomplicated falciparum malaria randomized to receive treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       artemether-lumefantrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"       sulfadoxine-pyrimethamine",
"      </a>",
"      , cure rates were 100, 97 and 93 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/21\">",
"       21",
"      </a>",
"      ]. Chloroquine plus sulfadoxine-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      was associated with a significantly longer parasite clearance time than those treated with the artemisinin regimens (2.9 versus 2.1 days).",
"     </li>",
"     <li>",
"      Among 601 Ugandan children with uncomplicated malaria randomized to receive amodiaquine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"       sulfadoxine-pyrimethamine",
"      </a>",
"      , amodiaquine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       artemether-lumefantrine",
"      </a>",
"      , the risk of recrudescence at 28 days was 14, 5, and 1 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/22\">",
"       22",
"      </a>",
"      ]. The efficacy of sulfadoxine-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      was even lower than that reported two years earlier in the same geographic locale, consistent with increasing resistance.",
"     </li>",
"     <li>",
"      Among 359 children in Tanzania treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       artemether-lumefantrine",
"      </a>",
"      , the drug was efficacious even after unsupervised treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Artemether-lumefantrine was approved for licensing by the United States Food and Drug Administration for the treatment of uncomplicated falciparum malaria in patients weighing &ge;5 kg in April 2009 as Coartmen [artemether (20 mg) and lumefantrine (120 mg), coformulated] [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/24\">",
"       24",
"      </a>",
"      ]. It is also licensed in Europe, Australia, and Southeast Asia. In five African countries, a new Coartem formulation of dispersible cherry-flavored tablets that dissolves readily in water was compared with crushed conventional tablets; the safety and efficacy profiles in the two groups were comparable [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/25\">",
"       25",
"      </a>",
"      ]. Dosing is summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       Artesunate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      &mdash; Multiple studies have demonstrated that treatment with artemisinin derivatives plus mefloquine (up to 25",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      is 90 to 100 percent effective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/28-34\">",
"       28-34",
"      </a>",
"      ]. In one study of 204 adults and children with acute uncomplicated falciparum malaria, the efficacy of artesunate and mefloquine given simultaneously for three days was equivalent to sequential therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/33\">",
"       33",
"      </a>",
"      ]. In another study of 394 patients in Thailand randomized to receive artesunate (600 or 640 mg over two days) plus mefloquine, artesunate alone (700 mg over five days), artemether alone (800 mg over five days),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      for seven days, or mefloquine alone, there were no differences among the treatment arms; cure rates were 92 to 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       Artesunate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       atovaquone-proguanil",
"      </a>",
"      &mdash; Among 1596 patients in Thailand with uncomplicated multidrug-resistant falciparum malaria randomized to receive treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      -proguanil, atovaquone-proguanil-artesunate, or artesunate-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      , all three regimens were highly effective and well-tolerated; recrudescence rates were lowest among those who received atovaquone-proguanil-artesunate [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Comparing ACTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, no artemisinin-containing combination regimen has been unequivocally proven to be superior to any other. The World Health Organization (WHO) favors the combinations outlined in the preceding section. Notable clinical trials comparing outcomes with artemisinin-containing regimens include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       Artemether-lumefantrine",
"      </a>",
"      versus dihydroartemisinin-piperaquine &mdash; There is substantial data comparing artemether-lumefantrine and dihydroartemisinin-piperaquine [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Among 754 patients in Papua, New Guinea with malaria (466 with P. falciparum, 175 with P. vivax, and 113 with a mixture of both species) randomized to receive artemether-lumefantrine or dihydroartemisinin-piperaquine, both regimens were found to be safe and were associated with a rapid clinical response [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Piperaquine has a much longer half-life than lumefantrine (28 versus 4 days). This relevance of this pharmacologic distinction was demonstrated in a randomized trial comparing artemether-lumefantrine and dihydroartemisinin-piperaquine among 232 young Ugandan children in a region of high transmission intensity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/37\">",
"       37",
"      </a>",
"      ]. The risk of recurrent parasitemia due to new infection was higher after 28 days of follow up among those treated with artemether-lumefantrine (35 versus 11 percent). However, the cumulative risk of recurrent malaria converged at 63 days of follow up. It is possible that in areas of moderate transmission intensity, the posttreatment prophylactic benefit of dihydroartemisinin-piperaquine provides some short term benefit. This has to be balanced with the concern that the longer drug half life may allow drug resistance selection to arise more easily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       Artesunate",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      versus dihydroartemisinin-piperaquine &mdash; Among 400 non-immune Vietnamese patients with uncomplicated P. falciparum malaria randomized to receive three days of artesunate plus mefloquine, dihydroartemisinin-piperaquine or dihydroartemisinin-trimethoprim-piperaquine, cure rates were similar in the three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/38\">",
"       38",
"      </a>",
"      ]. In another study of 180 Thai patients with uncomplicated falciparum malaria randomized to receive oral artesunate (4",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      plus mefloquine (8",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      or dihydroartemisinin (40 mg) plus piperaquine (320 mg) (in the form of Arteki) once a day for three days, all patients had rapid initial clinical and parasitological responses with no significant differences in fever clearance time or parasite clearance between both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyronaridine-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"       artemether-lumefantrine",
"      </a>",
"      &mdash; A randomized trial including 1272 children and adults from Africa and Asia demonstrated that both pyronaridine-artesunate and artemether-lumefantrine regimens resulted in a 28 day complete response rate of 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/40\">",
"       40",
"      </a>",
"      ]. Pyronaridine-artesunate was prescribed as single daily dose taken for three days; patients on this regimen had a significantly lower rate of new infections at day 28 and day 42, likely due to the prolonged half life of the pyronaridine component. The single day dosing and greater efficacy makes pyronaridine-artesunate an excellent addition to the ACT armamentarium [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyronaridine-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      versus artesunate-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      &mdash; Among 1271 patients in Asia and Africa, pyronaridine-artesunate was noninferior to mefloquine plus artesunate for treatment of uncomplicated P. falciparum malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a region of western Cambodia with a long history of artemisinin monotherapy, P. falciparum parasites have been found to have prolonged parasite clearance times relative to parasites in northwestern Thailand (where artemisinins have been used in combination therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Among 80 patients (40 in western Cambodia and 40 in northwestern Thailand) randomized to treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    monotherapy or combination therapy with artesunate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    , the median parasite clearance time was significantly higher in the Cambodian patients (84 versus 48 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/42\">",
"     42",
"    </a>",
"    ]. This was not correlated to a change in in vitro drug inhibition studies but nevertheless suggests the development of parasite populations that have decreased in vivo sensitivity to artemisinins.",
"   </p>",
"   <p>",
"    Subsequently, evidence of prolonged parasite clearance time in the setting of artemisinin use has been described in western Thailand; this is believed to have developed locally rather than by importation of resistant parasites from Cambodia, since no genotypes in Thailand matched those in western Cambodia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/44\">",
"     44",
"    </a>",
"    ]. This may forecast clinical drug resistance in the future.",
"   </p>",
"   <p>",
"    Widespread use of artemisinin monotherapy in the region is the most likely cause of the above observations. An intensive campaign has been launched by the World Health Organization (WHO) to contain artemisinin resistance, as there is no alternative class of malaria drugs to replace the artemisinin derivatives at this time. No improvement in parasite clearance has been observed with increasing the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    treatment dose (up to 8",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    or with splitting the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The result of a malaria blood smear on day 3 may be used as a simple screening measure for artemisinin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/46\">",
"     46",
"    </a>",
"    ]. Artemisinin resistance is unlikely if the proportion of patients with parasite density &lt;100,000",
"    <span class=\"nowrap\">",
"     parasites/microL",
"    </span>",
"    following a three-day course of therapy with an artemisinin combination regimen is less than 3 percent.",
"   </p>",
"   <p>",
"    In elimination areas (ie, low-transmission areas) and in areas threatened by artemisinin resistance, a single gametocidal dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    should be added to the artemisinin combination regimen as an adjunct for reduction of malaria transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/7,47-49\">",
"     7,47-49",
"    </a>",
"    ]. In 2012, the World Health Organization (WHO) recommended administration of primaquine (0.25 mg",
"    <span class=\"nowrap\">",
"     base/kg)",
"    </span>",
"    on the first day of treatment (except for pregnant women and infants &lt;12 months) in areas threatened by artemisinin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/47\">",
"     47",
"    </a>",
"    ]. This dose can be administered in the absence of testing for G6PD enzyme activity; further study of dosing efficacy is needed. Primaquine has activity against mature gametocytes but no effect on blood-stage parasites, and therefore, provides no treatment effect for the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atovaquone-proguanil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     Atovaquone-proguanil",
"    </a>",
"    is a well-tolerated and effective treatment for uncomplicated falciparum malaria in patients who were not taking this agent for prophylaxis during the period of exposure to malaria. It has been licensed for the treatment of malaria in the United States, Canada, Australia, and much of Europe.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     Atovaquone",
"    </a>",
"    selectively inhibits parasite mitochondrial electron transport and is combined with proguanil because of demonstrated synergism; resistance develops rapidly when atovaquone is used alone. Studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    conducted in Southeast Asia, South America and Africa have shown cure rates of &gt;95 percent with no severe adverse side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Several studies have demonstrated higher efficacy of the atovaquone-proguanil combination over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    and over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare reports of delayed parasite clearance have been associated with mutations in the parasite cytochrome gene (the therapeutic target) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/54\">",
"     54",
"    </a>",
"    ]. The cost has limited its use in resource limited, highly endemic settings.",
"   </p>",
"   <p>",
"    Dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Quinine based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, other treatments are preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    based regimens due to lower side effect profiles (ie, artemisinin combination therapy or malarone). However, quinine based regimens are effective for treatment of uncomplicated falciparum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    resistant malaria. The efficacy is greater than 90 percent in most areas of the world, except in parts of Southeast Asia, where resistance is prevalent and cure rates as low as 70 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Cure rates are also lower outside of research study settings, likely due to diminished compliance.",
"   </p>",
"   <p>",
"    Dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 1",
"    </a>",
"    ). The duration of treatment with quinine is generally three to seven days. Seven days should be given in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All cases of malaria acquired in Southeast Asia (since some degree of resistance is common).",
"     </li>",
"     <li>",
"      For all travelers from non-endemic areas, regardless of where infection was acquired, seven days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      should be administered in combination with one of the following:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      -sulfadoxine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (significant risk of recrudescent infection with shorter courses). This regimen may pose difficulties since seven days of quinine is often poorly tolerated and thus contributes to reduced compliance. Alternative therapies may need to be considered. For residents of endemic areas who acquire malaria outside Southeast Asia, three days of therapy is sufficient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    has a bitter taste and frequently causes cinchonism (reversible tinnitus and reversible high-tone hearing loss), making compliance with a full course problematic. Patients must be warned that these side effects are likely but that they will disappear following completion of the treatment course. In developing countries amodiaquine is sometimes used instead of quinine, but its efficacy is less certain; it is also associated with agranulocytosis (albeit uncommonly). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=see_link\">",
"     \"Antimalarial drugs: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Artemisinins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    are being used increasingly in place of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -based regimens because of the high frequency of side effects with quinine. In a study comparing the effectiveness of oral quinine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    for treatment of uncomplicated malaria among 175 Ugandan children, the cure rate for quinine was significantly lower than for artemether-lumefantrine (64 versus 96 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/58\">",
"     58",
"    </a>",
"    ]. Most of the treatment failures in the quinine group were late recrudescences (eg, relapse of infection with the original strain); adherence in the quinine group was also lower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mefloquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In concert with new treatment guidelines in highly endemic areas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    is typically used as a part of combination therapy (with another agent such",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or an artemisinin derivative) for treatment of uncomplicated falciparum malaria.",
"   </p>",
"   <p>",
"    Outside the Thai-Myanmar-Cambodia area,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    cures 90 to 95 percent of P. falciparum malaria. Within the Thai-Myanmar-Cambodia area, mefloquine cure rates have dropped to 60 percent due to resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/28,29,59\">",
"     28,29,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 1",
"    </a>",
"    ). Mefloquine is not recommended for children &lt;15 kg. Mefloquine can cause vomiting and neurologic toxicities including nightmares, ataxia, delirium and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/60\">",
"     60",
"    </a>",
"    ]. Twice daily dosing lessens the frequency of side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=see_link\">",
"     \"Antimalarial drugs: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potentially useful medications are limited by resistance and side effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"       Sulfadoxine-pyrimethamine",
"      </a>",
"      (Fansidar) is used in some endemic regions because of its low cost. However, it is a slow-acting drug and resistance is widespread [",
"      <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/61\">",
"       61",
"      </a>",
"      ]. As a result, it should not be used alone in non-immune returning travelers with falciparum malaria. Its use has also been associated with the development of the Stevens-Johnson syndrome.",
"     </li>",
"     <li>",
"      Halofantrine is a second-line agent. Since the drug has associated cardiotoxicity, it is used infrequently and should only be considered if no other drugs are available. Halofantrine is not marketed in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potential agents for the treatment of malaria under study or development include pyronaridine, an acridine derivative, malarial protease inhibitors, and macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimalarials considered safe in the first trimester of pregnancy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , proguanil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Of these, quinine remains the most effective and can be used in all trimesters of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1\">",
"     1",
"    </a>",
"    ]. We agree with the following WHO recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/41/25241/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First trimester:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"     </li>",
"     <li>",
"      Second and third trimesters: the ACT available in the region,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      and clindamycin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malaria in pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncomplicated malaria consists of symptomatic malaria without evidence of vital organ dysfunction and parasitemia &lt;5 percent, with the ability to take oral therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients for whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      -sensitive P. falciparum malaria can be predicted with certainty (",
"      <a class=\"graphic graphic_figure graphicRef72797 \" href=\"UTD.htm?38/32/39430\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef80738 \" href=\"UTD.htm?27/47/28406\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef67536 \" href=\"UTD.htm?37/6/37993\">",
"       figure 3",
"      </a>",
"      ), we suggest treatment with chloroquine (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In the setting of uncertain exposure history or unknown prevalence of chloroquine resistance, treatment for chloroquine resistant P. falciparum should be administered. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chloroquine sensitive malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to treatment of uncomplicated malaria due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      resistant P. falciparum depends on individual circumstances. Reasonable agents include artemisinin derivative combinations,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       atovaquone-proguanil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      -based regimens (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chloroquine resistant malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In highly endemic, drug resistant areas, we suggest treatment with artemisinin combination therapy to improve outcomes, reduce transmission, and limit drug resistance (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      based regimens are also acceptable; these agents are more frequently associated with adverse effects.",
"     </li>",
"     <li>",
"      In nonendemic areas we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       atovaquone-proguanil",
"      </a>",
"      or artemisinin combination therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      based regimens and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       mefloquine",
"      </a>",
"      are also acceptable agents; these drugs have a higher rate of adverse effects, which can reduce compliance. Patients on malaria prophylaxis should receive a different medication for treatment if they develop malaria infection.",
"     </li>",
"     <li>",
"      Artemisinin combination therapies (ACTs) are potent against all developmental stages of the asexual forms of malaria, resulting in the most rapid clearance time relative to other agents. In addition, ACTs are the primary class of drugs for treatment of uncomplicated falciparum malaria with activity against gametocytes, the stage responsible for continued transmission (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef79113 \" href=\"UTD.htm?18/53/19288\">",
"       figure 4",
"      </a>",
"      ). There are several oral artemisinin derivatives; overall no ACT has been unequivocally proven to be superior to any other. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Artemisinins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In elimination areas (ie, low-transmission areas) and in areas threatened by artemisinin resistance, we suggest that a single gametocidal dose (0.25 mg",
"      <span class=\"nowrap\">",
"       base/kg)",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      be added to the artemisinin combination regimen as an adjunct for reduction of malaria transmission (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       Atovaquone-proguanil",
"      </a>",
"      has a favorable side effect profile and is effective for treatment of uncomplicated falciparum malaria in patients who were not taking this agent for prophylaxis during the period of exposure to malaria (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Atovaquone-proguanil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the side effects associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      , artemisinins and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"       atovaquone-proguanil",
"      </a>",
"      are being used increasingly in place of quinine-based regimens. However, quinine-based regimens are also effective for the treatment of uncomplicated falciparum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      resistant malaria (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      ). The duration of treatment with quinine is generally three to seven days. Seven days should be given in the setting of malaria acquired in Southeast Asia and all travelers from non-endemic areas, regardless of where infection was acquired. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Quinine based regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      cures 90 to 95 percent of P. falciparum malaria outside the Thai-Myanmar-Cambodia area; within this region cure rates have dropped to 60 percent due to resistance. In highly endemic areas mefloquine is typically used as a part of combination therapy (with another agent such",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or an artemisinin derivative) for treatment of uncomplicated falciparum malaria (",
"      <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mefloquine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     WHO guidelines for the treatment of malaria. 2006, World Health Organization.",
"    </li>",
"    <li>",
"     file://www.cdc.gov/malaria/pdf/clinicalguidance.pdf (Accessed on December 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/3\">",
"      Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006; 355:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/4\">",
"      Newton P, White N. Malaria: new developments in treatment and prevention. Annu Rev Med 1999; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/5\">",
"      Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/6\">",
"      Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011; 52:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/7\">",
"      Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/8\">",
"      Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009; 8:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/9\">",
"      Sykes A, Hendriksen I, Mtove G, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 2009; 49:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/10\">",
"      Dunne MW, Singh N, Shukla M, et al. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 2005; 191:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/11\">",
"      Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 2010; 202:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/12\">",
"      Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/13\">",
"      Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J 2009; 8:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/14\">",
"      Jiao X, Liu GY, Shan CO, et al. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health 1997; 28:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/15\">",
"      Lef&egrave;vre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/16\">",
"      van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/17\">",
"      Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/18\">",
"      Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/19\">",
"      Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/20\">",
"      Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/21\">",
"      Mayxay M, Khanthavong M, Lindeg&aring;rdh N, et al. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin Infect Dis 2004; 39:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/22\">",
"      Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/23\">",
"      Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children &lt;5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011; 52:873.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/bbs/topics/NEWS/2009/NEW01989.html. (Accessed on April 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/25\">",
"      Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008; 372:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/26\">",
"      Omari AA, Gamble C, Garner P. Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2006; :CD005965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/27\">",
"      Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 2006; 74:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/28\">",
"      Looareesuwan S, Viravan C, Vanijanonta S, et al. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet 1992; 339:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/29\">",
"      Luxemburger C, ter Kuile FO, Nosten F, et al. Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/30\">",
"      Bunnag D, Kanda T, Karbwang J, et al. Two doses of artemether/mefloquine or artesunate/mefloquine combination for multidrug resistant falciparum Malaria. Southeast Asian J Trop Med Public Health 1997; 28:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/31\">",
"      Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/32\">",
"      Looareesuwan S, Wilairatana P, Viravan C, et al. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am J Trop Med Hyg 1997; 56:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/33\">",
"      Krudsood S, Looareesuwan S, Silachamroon U, et al. Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. Am J Trop Med Hyg 2002; 67:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/34\">",
"      Thimasarn K, Sirichaisinthop J, Chanyakhun P, et al. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand. Southeast Asian J Trop Med Public Health 1997; 28:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/35\">",
"      van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002; 35:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/36\">",
"      Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/37\">",
"      Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/38\">",
"      Tran TH, Dolecek C, Pham PM, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004; 363:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/39\">",
"      Tangpukdee N, Krudsood S, Thanachartwet W, et al. An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005; 36:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/40\">",
"      Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/41\">",
"      Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/42\">",
"      Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/43\">",
"      Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/44\">",
"      Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/45\">",
"      Das D, Tripura R, Phyo AP, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 2013; 56:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/46\">",
"      Stepniewska K, Ashley E, Lee SJ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010; 201:570.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.who.int/malaria/pq_updated_policy_recommendation_en_102012.pdf (Accessed on March 05, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/48\">",
"      Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013; 56:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/49\">",
"      Lawpoolsri S, Klein EY, Singhasivanon P, et al. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Malar J 2009; 8:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/50\">",
"      Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/51\">",
"      de Alencar FE, Cerutti C Jr, Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997; 175:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/52\">",
"      Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999; 179:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/53\">",
"      Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/54\">",
"      Kuhn S, Gill MJ, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg 2005; 72:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/55\">",
"      Pasvol G, Newton CR, Winstanley PA, et al. Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg 1991; 45:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/56\">",
"      Stanley J. Malaria. Emerg Med Clin North Am 1997; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/57\">",
"      Looareesuwan S, Wilairatana P, Vanijanonta S, et al. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet 1992; 339:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/58\">",
"      Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 2009; 339:b2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/59\">",
"      Maguire JD, Marwoto H, Richie TL, et al. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/60\">",
"      Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996; 42:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/61\">",
"      Barat LM, Bloland PB. Drug resistance among malaria and other parasites. Infect Dis Clin North Am 1997; 11:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/41/25241/abstract/62\">",
"      Rosenthal PJ. Proteases of malaria parasites: new targets for chemotherapy. Emerg Infect Dis 1998; 4:49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5704 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25241=[""].join("\n");
var outline_f24_41_25241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189103\">",
"      MANAGEMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H189157\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Chloroquine sensitive malaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Reversion of chloroquine resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chloroquine resistant malaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Artemisinins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Validating ACTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparing ACTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atovaquone-proguanil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Quinine based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mefloquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5704|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/32/39430\" title=\"figure 1\">",
"      Global distribution malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28406\" title=\"figure 2\">",
"      Malaria western hemisphere",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/6/37993\" title=\"figure 3\">",
"      Malaria eastern hemisphere",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19288\" title=\"figure 4\">",
"      Malaria life cycle drug targets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/63/33790\" title=\"table 1\">",
"      Treatment of uncomplicated malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20809?source=related_link\">",
"      Antimalarial drugs: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16473?source=related_link\">",
"      Epidemiology, prevention, and control of malaria in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39959?source=related_link\">",
"      Pathogenesis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_41_25242="Arteriovenous malformation I";
var content_f24_41_25242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54773%7EPULM%2F66530%7EPULM%2F81990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54773%7EPULM%2F66530%7EPULM%2F81990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation in the right upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal CT image with lung window settings shows a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation in the right upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT image with lung window settings shows a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation in the right upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal CT image with mediastinal window settings show a right upper lobe solitary pulmonary nodule with several tentacle-like extensions suspicious for an arteriovenous malformation. The enhancement of the nodule is identical to that of the central pulmonary arterial branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25242=[""].join("\n");
var outline_f24_41_25242=null;
var title_f24_41_25243="Five elements";
var content_f24_41_25243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five elements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fire",
"       </td>",
"       <td class=\"subtitle1\">",
"        Earth",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Water",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart",
"       </td>",
"       <td>",
"        Spleen",
"       </td>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardium",
"       </td>",
"       <td>",
"        Stomach",
"       </td>",
"       <td>",
"        Large intestine",
"       </td>",
"       <td>",
"        Bladder",
"       </td>",
"       <td>",
"        Gallbladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joy",
"       </td>",
"       <td>",
"        Anxiety",
"       </td>",
"       <td>",
"        Worry, grief",
"       </td>",
"       <td>",
"        Fear, depression",
"       </td>",
"       <td>",
"        Anger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Summer",
"       </td>",
"       <td>",
"        Late summer",
"       </td>",
"       <td>",
"        Autumn",
"       </td>",
"       <td>",
"        Winter",
"       </td>",
"       <td>",
"        Spring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirit",
"       </td>",
"       <td>",
"        Conscience",
"       </td>",
"       <td>",
"        Health",
"       </td>",
"       <td>",
"        Will",
"       </td>",
"       <td>",
"        Emotion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25243=[""].join("\n");
var outline_f24_41_25243=null;
var title_f24_41_25244="Defibrillation cardioversion tips";
var content_f24_41_25244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical tips for defibrillation and cardioversion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &bull; Precise coordination between CPR and defibrillation is essential to minimize the time between a chest compression and shock delivery as well as the time to resume compressions immediately after a shock.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Electrode pads offer several advantages over electrode paddles:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Designed to monitor the heart rhythm without the need for additional electrocardiogram electrodes that may interfere with pad placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - No need for application of creams or gels; arcing of electrical current is less likely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Not associated with sparks that may ignite fires",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - A rescuer is less likely to contact the patient's stretcher during shock delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Application of improper paddle pressure is eliminated as a possible reason for failure of defibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Paddles and electrode pads designed for adults should be used for children who weigh more than 10 kg. Of these, those 12 cm in diameter are superior to those that are 8 cm. Infant paddles or pads are to be used for smaller infants weighing &lt;10 kg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; When using paddles, use conductive materials such as electrode cream or paste to decrease transthoracic impedance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Interface materials that should not be used include saline, alcohol, and ultrasound gel, as well as the use of bare paddles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Paddles and electrode pads must not contact each other and care must be taken to avoid interface materials on one side of the chest contacting the material placed on the opposite side.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; The optimal energy dose for defibrillation in children has not been established. For manual defibrillators, use 2 J/kg for the first attempt, 4 J/kg for the second attempt, and 4 J/kg or higher for subsequent attempts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For synchronized cardioversion, use 0.5 to 1 J/kg for the first attempt and 2 J/kg for subsequent attempts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For AEDs, for children older than 8 years, a standard AED without a dose attenuator should be used. For those 1 to 8 years of age, an initial pediatric attenuated dose should be used. If it is the only device available, a standard AED without a dose attenuator is acceptable for those 1 to 8 years of age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; To avoid fires, all oxygen sources must be removed from the patient before defibrillation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25244=[""].join("\n");
var outline_f24_41_25244=null;
var title_f24_41_25245="Shoe shape PI";
var content_f24_41_25245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shoe shape must match foot shape",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 179px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25245=[""].join("\n");
var outline_f24_41_25245=null;
var title_f24_41_25246="Rib stress fracture bone scan";
var content_f24_41_25246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone scan of a rib stress fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bone scan of the chest wall is needed to diagnose rib stress fractures radiographically. A fracture is indicated by an area of increased radionuclide uptake (dark area on image above). Imaging is needed only in some cases where there is doubt about the diagnosis or when a definitive diagnosis is required to make decisions about returning to competition. The need for imaging will vary based on the clinician's experience managing rib stress fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristine Karlson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25246=[""].join("\n");
var outline_f24_41_25246=null;
var title_f24_41_25247="RV and late asthmatic reaction";
var content_f24_41_25247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rhinovirus and late asthmatic reaction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 490px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A comparison of FEV1 response to inhaled ragweed in patients without (left column) and with (right column) late asthmatic reaction (LAR) at baseline (upper panel), during acute rhinovirus upper respiratory infection (URI) (middle panel), and after recovery (lower panel). Only one of ten patients had an LAR at baseline versus eight of ten during acute URI (middle panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Lemanske, RF, Dick, EC, Swenson, CA, et al, J Clin Invest 1989; 83:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_41_25247=[""].join("\n");
var outline_f24_41_25247=null;
